Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

recurrent endometrial cancer
cancer therapy
recurrent disease
olaparib
platinum-based chemotherapy
  • 0 views
  • 19 Feb, 2024
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

Drugs used in chemotherapy, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

cisplatin
pemetrexed
multicentric castleman disease
sarcoma
squamous cell carcinoma
  • 0 views
  • 19 Feb, 2024
Pembrolizumab Plus Paclitaxel Cisplatin Followed by Surgery for Locally Advanced ESCC

The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.

cisplatin
pembrolizumab injection
serum pregnancy test
pembrolizumab
squamous cell carcinoma of esophagus
  • 0 views
  • 19 Feb, 2024
Cryoablation Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Giving cryoablation, atezolizumab and nab-paclitaxel may improve response to the disease.

chemotherapy regimen
triple negative breast neoplasms
anatomic stage iiic breast cancer ajcc v8
atezolizumab/nab-paclitaxel
estrogen
  • 0 views
  • 19 Feb, 2024
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

This randomized phase II study will evaluate the efficacy of nivolumab plus paclitaxel for first-line treatment of recurrent or metastatic HNSCC in the platinum ineligible and platinum refractory settings. Control arm will be paclitaxel in combination with cetuximab, treatment included in the guidelines of the Spanish Society of Medical Oncology.

cisplatin
autoimmune thyroiditis
oropharyngeal
immunosuppressive agents
caries
  • 0 views
  • 19 Feb, 2024
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

drug test
breast ductal carcinoma
pancreatic cancer
antineoplastic agents
azacitidine
  • 0 views
  • 19 Feb, 2024
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer

The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.

cisplatin
chemoradiation therapy
cervical cancer stage
immunomodulator
cancer
  • 0 views
  • 19 Feb, 2024
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

shr-1210
measurable disease
cisplatin
antibody therapy
monoclonal antibodies
  • 0 views
  • 19 Feb, 2024
SeQuent Please Neo Multicenter Registry

The registry evaluates the safety and efficacy of paclitaxel-releasing SeQuent Please Neo balloon in the following scenarios: restenosis, bifurcation lesions, small vessel lesions, diabetes (diffuse disease) and atrial fibrillation.

  • 0 views
  • 19 Feb, 2024